Search Skin Biology
Many websites promote the use of ingredients such as EGF in skin products. You could be purchasing cosmetic cigarettes without your knowledge! By cosmetic cigarettes we mean products that may damage your health in 10 to 20 years.
There are many so-called "scientifically-proven" cosmeceuticals that emphasize use of foreign compounds or "new ingredients" designed to "activate youth genes", "repair DNA", or employ "new technology that reverses cell aging". The problem is that activating regenerative genes may also activate cancer genes or other toxic genes. The only safe skin products in this regard appear to be retinoic acid and peptides produced by tissue breakdown after wound healing such as GHK-copper. One wound growth factor called PDGF was used for wound healing and cosmetics, but later was found to promote cancer growth. EGF is used in skin products but thousands of articles indicate EGF may promote the growth of breast cancer. It also damages hair follicles and cause hair loss. See table below. 
However, similar to the hundreds of foreign agents in cigarettes, these "revolutionary products" containing "new" artificial compounds that your body has no background of being able to assimilate, the danger lies in what these ingredients are actually doing over the long term in your body.
In many cosmetics, potent cancer causing ingredients have already been sold. This should concern all of us since 2.2 kg of cosmetic ingredients enter the average woman's body each year.
The real question is: What happens 10-20 years later after one has exposed themselves to such compounds for so long?
| REFERENCES | ||
| RETINOIC ACID |
Widely used for skin remodeling and in anti-cancer therapy |
Go to "Pubmed" and search "retinoic acid cancer" |
| GHK-COPPER | Used for skin regeneration and remodeling |
Suppresses cancer growth in cultured cancer cells and in mice. Induces 84 human genes in an anti-cancer pattern. See: www.skinbiology.com/copper-peptides-cancer-metastasis-suppression.html |
| PDGF (Platelet Derived Growth Factor) |
Was used in cosmetics and was FDA approved for human wound healing |
Starts or speeds cancer growth / Go to "Pubmed" and search "PDGF cancer". |
| EGF (Epidermal Growth Factor) |
Used in cosmetics but stimulates breast cancer growth. It also damages hair follicles and causes hair loss. |
Go to "Pubmed" and search "EGF breast cancer". See 2,187 articles. May promote breast cancer growth. |
Below are abstracts of two of the thousands of articles on PDGF and cancer.
Platelet-derived growth factor regulates breast cancer progression via β-catenin expression.
Pathobiology. 2011;78(5):253-60. doi: 10.1159/000328061. Epub 2011 Aug 17.
Yokoyama Y1, Mori S, Hamada Y, Hieda M, Kawaguchi N, Shaker M, Tao Y, Yoshidome K, Tsujimoto M, Matsuura N.
ABSTRACT
OBJECTIVE: The knowledge on the association between platelet-derived growth factor (PDGF) signaling and epithelial cancers is scarce, although overexpression of PDGF and PDGF receptors has been reported in some human mesenchymal tumors. Thus, we studied the effect of PDGF on breast cancer cells in vitro and the distribution of PDGF in breast cancer tissues.
METHODS: The effect of PDGF-BB on breast cancer cells was assessed by Western blotting, immunofluorescence, WST and 5-bromo-2-deoxyuridine incorporation experiments. PDGF-B and β-catenin expression was investigated in breast cancer tissues by immunohistochemistry.
RESULTS: PDGF-BB induces β-catenin expression in breast cancer cells, and immunohistochemically the distribution of PDGF-B was similar to β-catenin in breast cancer cells. PDGF-B-positive cancer cells were more frequent in cases of ductal carcinoma in situ (87.5%) than invasive carcinoma (61.2%). In addition, PDGF-B staining was stronger in intraductal than invasive cancer cells. PDGF-BB tended to induce nuclear translocation of β-catenin, cell proliferation and DNA incorporation in MDA-MB231 cells, while these results were not found in MCF-7 cells.
CONCLUSION: Our results suggest that PDGF-BB regulates protein expression of β-catenin and is associated with cancer cell behavior.
PDGF Receptors as Targets in Tumor Treatment Arne Ostman* and Carl‐Henrik Heldin {*Department of Pathology‐Oncology, Cancer Center Karolinska, Karolinska Institutet, R8:03, SE‐171 76 Stockholm, Sweden; {Ludwig Institute for Cancer Research, Uppsala University, SE‐751 24 Uppsala, Sweden I. Molecular Biology of PDGF A. PDGF Isoforms and PDGF Receptors B. Signaling via PDGF Receptors II. Physiological Roles of PDGF III. Roles of PDGF Receptors in Tumors A. PDGF Stimulation of Malignant Cells B. Tumor Angiogenesis and PDGF Receptor Signaling C. PDGF and Recruitment of Tumor Fibroblasts D. Regulation of Tumor Drug Uptake and IFP by PDGF Receptors E. Implications of Roles for PDGF Receptor Signaling in Metastasis IV. Clinical Studies A. PDGF Antagonists B. Clinical Effects Ascribed to PDGF Receptor Inhibition
Insulin-Like Growth Factor and Epidermal Growth Factor Signaling in Breast Cancer Cell Growth: Focus on Endocrine Resistant Disease.
Anal Cell Pathol (Amst). 2015;2015:975495. doi: 10.1155/2015/975495. Epub 2015 Jul 15.
Voudouri K1, Berdiaki A1, Tzardi M2, Tzanakakis GN1, Nikitovic D1.
ABSTRACT: Breast cancer is the most common type of cancer for women worldwide with a lifetime risk amounting to a staggering total of 10%. It is well established that the endogenous synthesis of insulin-like growth factor (IGF) and epidermal growth factor (EGF) polypeptide growth factors are closely correlated to malignant transformation and all the steps of the breast cancer metastatic cascade. Numerous studies have demonstrated that both estrogens and growth factors stimulate the proliferation of steroid-dependent tumor cells, and that the interaction between these signaling pathways occurs at several levels. Importantly, the majority of breast cancer cases are estrogen receptor- (ER-) positive which have a more favorable prognosis and pattern of recurrence with endocrine therapy being the backbone of treatment. Unfortunately, the majority of patients progress to endocrine therapy resistant disease (acquired resistance) whereas a proportion of patients may fail to respond to initial therapy (de novo resistance). The IGF-I and EGF downstream signaling pathways are closely involved in the process of progression to therapy resistant disease. Modifications in the bioavailability of these growth factors contribute critically to disease progression. In the present review therefore, we will discuss in depth how IGF andEGF signaling participate in breast cancer pathogenesis and progression to endocrine resistant disease.
for w
What Are True Skin Rejuvenating Copper Peptides?
Rejuvenating copper peptides are small protein fragments that can bind copper 2+ ions. When used in topical cosmetic products they result in very positive for skin rejuvenation. These are GHK (glycyl-l-histidyl-l-lysine) and the mixed second generation copper products promote skin health.
However, not all copper peptides help the skin. Some snake venoms contain very toxic copper peptides.
These are copper peptides, that have been shown to improve to help skin beauty and condition, have been heavily tested by leading dermatologists and the results in published in journals. I have has researched copper peptides and their biological actions for over 45 years, am still researching to this very day, and published many papers and patents of them.
Questions or Advice?
Email Dr. Loren Pickart at drlorenpickart@gmail.com
Call us at 1-800-405-1912 Monday Through Friday (8 am to 6 pm) PST
